The advent of immune checkpoint inhibitors (ICIs), such as anti-programmed cell death protein 1 (PD-1) and anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antibodies (Abs), has revolutionized the treatment of patients with advanced melanoma. Here, CTLA4 is linked to melanoma.